Nemucore Medical Innovations to Present at 2nd Annual Ladenburg Thalmann Healthcare Conference

 
 
Spread the Word
Listed Under

Tags:
Biotechnology
Pharmaceuticals
Oncology

Industry:
Biotech

Location:
Wellesley - Massachusetts - US

WELLESLEY, Mass. - Sept. 26, 2016 - PRLog -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women's cancers, announced today that Timothy P. Coleman, President and Chief Executive Officer, will present a corporate overview and update at the 2nd Annual Ladenburg Thalmann Healthcare Conference on September 27th in New York City. The Nemucore presentation will take place at 10:30 AM.

About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women's cancers. Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late-2016. Two additional candidates are anticipated to enter clinical trial development later in 2017, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at http://www.Nemucore.com.

About Ladenburg
Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS, LTS PrA) is a publicly-traded diversified financial services company based in Miami, Florida. Ladenburg's subsidiaries include industry-leading independent broker-dealer firms Securities America, Inc., Triad Advisors, Inc., Securities Service Network, Inc., Investacorp, Inc. and KMS Financial Services, Inc., as well as Premier Trust, Inc., Ladenburg Thalmann Asset Management Inc., Highland Capital Brokerage, Inc., a leading independent life insurance brokerage company, and Ladenburg Thalmann & Co. Inc., an investment bank which has been a member of the New York Stock Exchange for 135 years. The company is committed to investing in the growth of its subsidiaries while respecting and maintaining their individual business identities, cultures, and leadership. For more information, please visit http://www.ladenburg.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=ht...).

Contact
Tim Coleman (investors)
Nemucore Medical Innovations
***@nemucore.com
(508) 762-1017
End
Email:***@nemucore.com Email Verified
Tags:Biotechnology, Pharmaceuticals, Oncology
Industry:Biotech
Location:Wellesley - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Nemucore Medical Innovations PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share